Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navitoclax with or without ruxolitinib in myelofibrosis
NCT03222609Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2017
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, open-label trial of navitoclax in myelofibrosis (MF) (4 cohorts), sponsored by AbbVie Inc. Primary endpoint: Spleen Volume Reduction ≥35% at 24 weeks. Started Oct 2017; status: completed.
02
Drugs
navitoclax
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT03222609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03222609.